AroCell announces interim report three will be brought forward

The board of directors of AroCell AB (publ) has taken a decision to bring forward interim report three to November 10, 2015 (previously November 17, 2015) as a consideration to the planned preferential rights issue.

 

For further information:

Jan Stålemark, CEO
AroCell AB (pub)
Tel: +46-706696206
info@arocell.com
www.arocell.com

 

About AroCell AB (publ)
AroCell AB is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please see www.arocell.com . AroCell AB is listed at AktieTorget and has about 2 300 shareholders.

 

Interim report three will be brought forward, PDF

Interim report three will be brought forward in Swedish, PDF